Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
Cellectar Biosciences (NASDAQ: CLRB) said a Phase 1 open-label study of iopofosine I 131 plus low-dose dexamethasone in 31 relapsed or refractory multiple myeloma patients was published in Cancers. Among 26 efficacy-evaluable patients, 84.6% had stable disease or better, with a 30% overall response rate in those receiving at least 60 mCi. Safety was manageable, mainly reversible cytopenias.
How this was made
The 30-second read
Why it matters
The publication highlights manageable cytopenia-driven toxicity, low non-hematologic adverse events, and observed disease control/response in heavily pretreated multiple myeloma patients. It also specifies a recommended fractionated Phase 2 regimen, which can help de-risk protocol planning in the market’s view.
Market read
For CLRB traders, the main value is incremental clinical validation and a clearer path to Phase 2 dosing, but the article reads as a publication of Phase 1 findings rather than a brand-new trial readout.
What to watch
Key near-term drivers remain trial progression, enrollment/operational updates, and whether the recommended fractionated Phase 2 regimen reproduces the response signal with durable outcomes.
Background
Cellectar is developing iopofosine I 131, a targeted radiotherapeutic using its phospholipid drug conjugate platform, across multiple B-cell malignancies.
Ticker impact
Cellectar published Phase 1 results for iopofosine I 131 plus low-dose dexamethasone in 31 relapsed/refractory multiple myeloma patients, reporting manageable toxicity and response rates.
Modest near-term support for CLRB sentiment, with follow-through likely dependent on upcoming Phase 2 execution and any new efficacy/safety updates.
The article provides specific Phase 1 efficacy and safety figures (stable disease rate, ORR, cytopenia profile) and a recommended fractionated Phase 2 regimen, which can move biotech sentiment. However, it is framed as publication of Phase 1 study results, which often reduces incremental novelty versus a first-time disclosure.
Market effects
Adds to the targeted radiotherapeutic and phospholipid drug conjugate narrative in hematologic oncology, potentially supporting the broader sentiment for similar modality developers.
No clear regional market linkage beyond US small/mid-cap biotech investor attention.
Limited global read-across; the data are specific to Cellectar’s program and indication set.
Counterpoint
Phase 1 results and publication may not change the fundamental risk profile materially; investors may discount the news until Phase 2 efficacy is demonstrated.
Key entities
- companyCellectar Biosciences, Inc.
NASDAQ-listed biopharmaceutical company publishing Phase 1 results for iopofosine I 131 in relapsed/refractory multiple myeloma.
- drug_programIopofosine I 131
Iodine-131 targeted radiotherapeutic evaluated in Phase 1 with low-dose dexamethasone.
- drugDexamethasone
Low-dose steroid used in combination with iopofosine I 131 in the Phase 1 trial.
